Halozyme Names Barbara Duncan to Bd of Directors
Mutual of America Capital Management LLC Sells 12,146 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Mutual of America Capital Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 5.9% during the 3rd quarter, according to the company in its most recent
Is Halozyme Therapeutics (HALO) a Growing Stock to Invest In?
Argenx Stock Dips as FDA Extends Review Period for Subcutaneous Efgartigimod
S&P 500 Futures Flat In Premarket Trading; Masimo, World Wrestling Lead
This article was automatically generated by Barrons.com using technology from Automated Insights. Corrections & Amplifications: A previous version of this article misstated the moves for gold futures
Multiple Reasons For the Outperformance of Halozyme Therapeutics (HALO)
Investors in Halozyme Therapeutics (NASDAQ:HALO) Have Made a Splendid Return of 168% Over the Past Three Years
It might be of some concern to shareholders to see the Halozyme Therapeutics, Inc. (NASDAQ:HALO) share price down 10% in the last month. In contrast, the return over three years has been impressive
Is Halozyme Therapeutics (HALO) a High Growth Company?
Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) CEO Helen Torley sold 10,000 shares of the company's stock in a transaction on Thursday, January 19th. The stock was sold at an average price of
Insider Sell: Halozyme Therapeutics
05:11 PM EST, 01/19/2023 (MT Newswires) -- Helen Torley, Director, President and CEO, on January 17, 2023, sold 30,000 shares in Halozyme Therapeutics (HALO) for $1,539,149. Following the Form 4 filin
Loading...
No Stock Yet